SEC Form 4 · accession 0001144204-15-001867
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Sidransky
Director
Period of report
Jan 8, 2015
Accepted (ET)
Jan 12, 2015 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted StockF1 | Jan 8, 2015 | A | 3,409 | $0.00 | A | 21,699 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3,F2 | $2.20 | Jan 8, 2015 | A | 50,000 | A | — | Jan 8, 2025 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The shares restricted stock were granted as monthly consideration for services rendered by the Reporting Person as Chairman of the Executive Committee of the Board. All shares of restricted stock vested upon grant.
- F2The stock options shall vest quarterly over a three-year period, with 1/3 of the stock options granted vesting annually commencing on January 8, 2015.
- F3These securities were issued as part of the Issuer's annual equity compensation to non-employee directors.